Henry Chen, MD
Interventional Cardiology · Huntsville, ALNPI 1750351169
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 441 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by Novartis at 24.2% of the total.
Across 441 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Boston Scientific$946
- Johnson & Johnson$790
- Amgen$584
- Pfizer$549
- Boehringer Ingelheim$429
- plus $3K from 23 others
Across 13 payments — averaging $10,665 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$104K
- Novartis$34K
What the payments were for
- Food & beverage$7,860100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 104 | $1,899 |
| Boston Scientific | 57 | $946 |
| Johnson & Johnson | 50 | $790 |
| Amgen | 36 | $584 |
| Pfizer | 26 | $549 |
| Boehringer Ingelheim | 20 | $429 |
| E.r. Squibb & Sons, L.L.C. | 18 | $285 |
| Novo Nordisk | 13 | $230 |
| AstraZeneca | 14 | $210 |
| Gilead | 17 | $207 |
| Regeneron Healthcare Solutions, Inc. | 9 | $198 |
| Sanofi-aventis U.S. LLC | 11 | $185 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $183 |
| Cardiovascular Systems Inc. | 6 | $169 |
| Medtronic | 9 | $163 |
| Bayer | 8 | $159 |
| Otsuka America Pharmaceutical, Inc. | 6 | $136 |
| Abbott | 6 | $119 |
| Esperion Therapeutics, Inc. | 6 | $112 |
| Abiomed | 2 | $52 |
| Chiesi USA, Inc. | 4 | $52 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Lundbeck LLC | 2 | $34 |
| United Therapeutics Corporation | 1 | $32 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Shockwave Medical, Inc | 1 | $18 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$146
- JARDIANCE$110
How this compares
$7,860 in reported general payments places this provider in the 55th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 439 | $379,918 |
| EntrestoSacubitril/Valsartan | 270 | $231,007 |
| XareltoRivaroxaban | 107 | $110,571 |
| CamzyosMavacamten | 12 | $104,456 |
| FarxigaDapagliflozin Propanediol | 109 | $93,476 |
| JardianceEmpagliflozin | 49 | $55,371 |
| Repatha SureclickEvolocumab | 72 | $48,875 |
| Ranolazine ErRanolazine | 448 | $39,333 |
| Rosuvastatin Calcium | 785 | $13,358 |
| Prasugrel Hcl | 146 | $9,151 |
| Metoprolol Succinate | 592 | $8,913 |
| Valsartan | 215 | $6,749 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 230 | $5,744 |
| ClopidogrelClopidogrel Bisulfate | 554 | $5,408 |
| Atorvastatin Calcium | 310 | $4,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $549 | $379,918439 claims |
| NovartisEntresto | $1,899 | $231,007270 claims |
| Johnson & JohnsonXarelto | $790 | $110,571107 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $285 | $104,45612 claims |
| AstraZenecaFarxiga | $210 | $93,476109 claims |
| Boehringer IngelheimJardiance | $429 | $55,37149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Huntsville
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Alejandro VasquezHuntsville$45K
- David DrenningHuntsville$31K
- Clarence GillHuntsville$13K
- Victor OkunrintemiHuntsville$12K
- Mihir KanitkarHuntsville$7K
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.